Treatment implications of the emerging molecular classification system for melanoma

The Lancet Oncology

Volumn 12, Issue 9, 2011, Pages 913-922

  Romano, Emanuela ^a   Schwartz, Gary K ^a   Chapman, Paul B ^a   Wolchock, Jedd D ^a   Carvajal, Richard D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CHIR 265; DACARBAZINE; DASATINIB; GSK 1120212; GSK 2118436; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MK 2206; NILOTINIB; RO 5185426; SELUMETINIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UO 126; XL 281;

ANTINEOPLASTIC ACTIVITY; APAF1 GENE; AREA UNDER THE CURVE; ARTHRALGIA; CANCER CLASSIFICATION; CCND1 GENE; CDKN2A GENE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CUTANEOUS MELANOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; EPIGENETICS; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HISTOPATHOLOGY; HUMAN; IC 50; MELANOMA; MITF GENE; MOLECULAR CLASSIFICATION SYSTEM; MULTIPLE CYCLE TREATMENT; ONCOGENE; ONCOGENE AKT3; ONCOGENE BRAF; ONCOGENE GNA11; ONCOGENE GNAQ; ONCOGENE N RAS; PATHOGENESIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGNOSIS; PTEN GENE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TP53 GENE; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; GENETIC PREDISPOSITION TO DISEASE; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; INDIVIDUALIZED MEDICINE; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT; SIGNAL TRANSDUCTION; TERMINOLOGY AS TOPIC;

EID: 80052358465     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70274-6     Document Type: Review

References (78)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
4. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
5. Barnhill RL, Fine JA, Roush GC, Berwick M Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996, 78:427-432.
6. McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973, 32:1446-1457.
7. Ackerman AB Malignant melanoma: a unifying concept. Hum Pathol 1980, 11:591-595.
8. Clark WH, From L, Bernardino EA, Mihm MC The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969, 29:705-727.
9. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A Cutaneous malignant melanoma. Mayo Clin Proc 2006, 81:500-507.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
11. Whiteman DC, Parsons PG, Green AC p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998, 77:843-848.
12. Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003, 95:806-812.
13. Rivers JK Is there more than one road to melanoma?. Lancet 2004, 363:728-730.
14. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
16. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003, 95:1878-1890.
17. Bohm M, Moellmann G, Cheng E, et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995, 6:291-302.
18. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005, 65:4005-4011.
19. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472.
20. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
21. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
22. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
23. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. Proc Am Soc Clin Oncol 2010, 28:8511. (abstr).
24. Malek S Selective inhibition of Raf results in downregulation of the Ras/Raf/MEK/ERK pathway and inhibition of tumor growth in vivo. Eur J Cancer Suppl 2006, 4(12):184.
25. Schwartz GK, Robertson S, Shen A, et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2009, 27:3513. (abstr).
26. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc Am Soc Clin Oncol 2010, 28:8503. (abstr).
27. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008, 105:3041-3046.
28. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
29. Chapman P, Puzanov I, Sosman J, et al. Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032. Eur J Cancer Suppl 2009, 7(3):5.
30. Melanoma 2010 Congress. Pigment Cell Melanoma Res 2010, 23:874-1004. Anon.
31. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kB, and stress-activated protein kinase. J Immunol 1998, 160:1116-1121.
32. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
33. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
34. Smalley KS, Xiao M, Villanueva J, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009, 28:85-94.
35. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007, 13:1576-1583.
36. Friday BB, Yu C, Smith PD, Adjei AA A potential role for modulation of a negative feedback loop between Erk and Raf in mediating sensitivity to the MEK inhibitor AZD6244 (ARRY-142886) in human lung cancer cell lines. Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; Washington, DC, USA; April 1-5, 2006 2006, 1143-1144. AACR, Philadelphia, (abstract 4868).
37. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008, 26:2139-2146.
38. Wee S, Jagani Z, Xiang KX, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
39. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. Proc Am Soc Clin Oncol 2008, 26:9033. (abstr).
40. Xiao L, Yang YB, Li XM, Xu CF, Li T, Wang XY Differential sensitivity of human endometrial carcinoma cells with different PTEN expression to mitogen-activated protein kinase signaling inhibits and implications for therapy. J Cancer Res Clin Oncol 2010, 136:1089-1099.
41. Thompson DS, Flaherty K, Messersmith W, et al. A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma. Proc Am Soc Clin Oncol 2009, 27:14584. (abstr).
42. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. Proc Am Soc Clin Oncol 2010, 28:2503. (abstr).
43. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987, 6:3341-3351.
44. Grabbe J, Welker P, Dippel E, Czarnetzki BM Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res 1994, 287:78-84.
45. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992, 52:197-201.
46. Montone KT, van Belle P, Elenitsas R, Elder DE Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997, 10:939-944.
47. Curtin JA, Busam K, Pinkel D, Bastian BC Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
48. Handolias D, Salemi R, Murray W, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res 2010, 23:210-215.
49. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774.
50. Hornick JL, Fletcher CD The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 2007, 38:679-687.
51. Demetri GD Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002, 38(suppl 5):S52-S59.
52. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106:2005-2011.
53. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92:1398-1405.
54. Fecher LA, Nathanson K, Flaherty KT, et al. Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma. Proc Am Soc Clin Oncol 2008, 26:9059. (abstr).
55. Schuchter L, Flaherty K, Davidson R, et al. Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. Proc Am Soc Clin Oncol 2004, 22:7572. (abstr).
56. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051.
57. Lutzky J, Bauer J, Bastian BC Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008, 21:492-493.
58. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009, 8:2079-2085.
59. Minor DR, O'Day S, Kashani-Sabet M, Daud A, Salman Z, Bastian B Sunitinib therapy for metastatic melanomas with KIT aberrations. Proc Am Soc Clin Oncol 2010, 28:8545. (abstr).
60. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010, 102:1219-1223.
61. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. Proc Am Soc Clin Oncol 2009, 27:9001. (abstr).
62. Guo J, Si L, Kong Y, et al. A phase II study of imatinib for advanced melanoma patients with KIT aberrations. Proc Am Soc Clin Oncol 2010, 28:8527. (abstr).
63. Chernoff KA, Bordone L, Horst B, et al. GAB2 amplifications refine molecular classification of melanoma. Clin Cancer Res 2009, 15:4288-4291.
64. Horst B, Gruvberger-Saal SK, Hopkins BD, et al. Gab2-mediated signaling promotes melanoma metastasis. Am J Pathol 2009, 174:1524-1533.
65. Burgess MR, Sawyers CL Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal 2006, 6:918-930.
66. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009, 15:5902-5909.
67. Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008, 47:853-859.
68. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007, 121:257-264.
69. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:4874-4881.
70. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005, 92:2032-2038.
71. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009, 457:599-602.
72. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH, Barsh GS Effects of G-protein mutations on skin color. Nat Genet 2004, 36:961-968.
73. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008, 49:5230-5234.
74. Bastian BC. G-protein mutations in uveal melanoma and intradermal melanocytic proliferations. Presented at 101st Annual Meeting of the American Association for Cancer Research; Washington, DC, USA; April 17-21, 2010.
75. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010, 363:2191-2199.
76. Ambrosini G. The MEK inhibitor AZD6244 is active in GNAQ mutant ocular melanoma cells. 101st Annual Meeting of the American Association for Cancer Research; Washington, DC, USA; April 17-21, 2010. Abstract 5035.
77. Prickett TD, Agrawal NS, Wei X, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009, 41:1127-1132.
78. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003, 100:8372-8377.